Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

American Society of Hematology 2016 annual meeting

American Society of Hematology 2016 annual meeting At the last meeting of the American Society of Hematology (ASH), data on first-line treatment with obinutuzumab in indolent lymphoma, as well as promising data on the long-term observation of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib, were presented. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

American Society of Hematology 2016 annual meeting

Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/american-society-of-hematology-2016-annual-meeting-a09erKGW9c
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0340-6
Publisher site
See Article on Publisher Site

Abstract

At the last meeting of the American Society of Hematology (ASH), data on first-line treatment with obinutuzumab in indolent lymphoma, as well as promising data on the long-term observation of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib, were presented.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 19, 2017

References

  • New treatment options have changed the survival of patients with follicular lymphoma
    Fisher, RI
  • Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B‑cell cytotoxicity
    Mössner, E
  • Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: primary results of the randomized phase 3 GALLIUM study
    Marcus, RE
  • Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with Rituximab-refractory indolent non-Hodgkin Lymphoma: updated results of the GADOLIN study
    Cheson
  • Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
    Burger
  • Updated efficacy and safety from the phase 3 resonate-2 study: Ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia
    Barr, PM
  • Five-year experience with single-agent Ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia
    O’Brien, SM
  • Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to Ibrutinib or idelalisib
    Jones, J
  • Outcome of patients with complex karyotype in a phase 3 randomized study of Idelalisib plus rituximab for relapsed chronic lymphocytic leukemia
    Kreuzer
  • Lenalidomide maintenance after front line therapy substantially prolongs progression free survival in high risk CLL: interim results of a phase 3 study (CLL M1 study of the German CLL study group)
    Fink
  • Results of the phase 3 study of Lenalidomide versus placebo as maintenance therapy following second-line treatment for patients with chronic lymphocytic leukemia (the CONTINUUM trial)
    Foa
  • Acalabrutinib monotherapy in patients with Ibrutinib intolerance: results from the phase 1/2 ACE-CL-001 clinical study
    Awan
  • Phase III randomized study of R‑CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B‑cell lymphoma: CALGB/alliance 50303
    Wilson, WH
  • Obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B‑cell lymphoma: final results from an open-label, randomized phase 3 study (GOYA)
    Vitolo, U
  • First analysis of an international double-blind randomized phase III study of lenalidomide maintenance in elderly patients with DLBCL treated with R‑CHOP in first line, the Remarc study from Lysa
    Thieblemont
  • LBA-6 Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B‑cell Lymphoma (DLBCL): results from the pivotal phase 2 ZUMA-1
    Neelapu, SS
  • Ibrutinib monotherapy in relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreo-retinal lymphoma (PVRL). Result of the interim analysis of the iLOC phase II study from the Lysa and the French LOC network
    Choquet, S
  • Single-agent ibrutinib in recurrent/refractory central nervous system lymphoma
    Grommes, Ch
  • Rituximab-Lenalidomide (REVRI) in relapse or refractory primary central nervous system (PCNSL) or vitreo retinal lymphoma (PVRL): results of a “proof of concept” phase II study of the French LOC network
    Ghesquieres, H
  • Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: final results of the randomized phase 3 lyma trial of the Lysa/Goelams group
    Gouill, S